Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Expression of p16 in serous ovarian neoplasms
H. O. Nazlioglu1,*, İ. Ercan2, T. Bilgin3, S. Ozuysal1
1 Department of Pathology, Uludag University School of Medicine, Bursa
2 Department of Biostatistics, Uludag University School of Medicine, Bursa
3 Department of Gynecology and Obstetrics, Uludag University School of Medicine, Bursa (Turkey)
Eur. J. Gynaecol. Oncol. 2010, 31(3), 312–314;
Published: 10 June 2010
Purpose: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues. Materials and Methods: p16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue. The results were also compared with histopathological grade in serous adenocarcinomas. Results: p16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively. It was significantly higher in carcinomas (p < 0.001) and borderline tumors (p < 0.001) compared to cystadenomas. No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells. The percentage of p16 expression did not change significantly with histological grade in carcinomas. Conclusion: p16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.
Ovarian serous carcinoma